At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
3BNC117 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open Label Study of the Safety, Antiretroviral Activity and Pharmacokinetics of 3BNC117 During a Short Analytical Treatment Interruption in HIV-infected Subjects
In Brief
A Phase 2 clinical trial evaluating 3BNC117 and ART Interruption for HIV-1 Infection. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This study evaluates the effects of two infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART and its safety during a brief analytical interruption of antiretroviral therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedMay 2015
Primary CompletionMar 2017
TodayJul 2026
First PostedMay 18, 2015
Enrollment StartMar 11, 2015
Primary CompletionMar 25, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 11.1 years ago
Interventions
3BNC117drug
3BNC117 infusions
ART Interruptionother
Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.